A Swedish study published in Nature Medicine indicates that repurposing a Parkinson's medication as an add-on therapy may alleviate motivation and anhedonia symptoms in patients with treatment-resistant depression.
Lumateperone is associated with a reduced risk of relapse in patients with schizophrenia, supporting its efficacy as a maintenance treatment.
A randomized controlled trial demonstrates that the dopamine agonist pramipexole significantly reduces anhedonia in patients with mood disorders when used as an augmentation strategy.
Real-world data indicates psilocybin offers clinical benefit for treatment-resistant depression, supporting its potential role in psychiatric pharmacotherapy.
This case report describes the successful use of zolpidem to treat severe refractory insomnia in a critically ill patient with delirium, challenging the general avoidance of Z-drugs in this population when sleep disruption perpetuates cognitive decline.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 10 – Jun 12)
- Consider augmenting treatment-resistant depression with pramipexole to specifically target residual anhedonia and motivation deficits.
- Utilize lumateperone as a maintenance strategy for schizophrenia given its demonstrated efficacy in reducing relapse risk.
- Evaluate baseline inflammatory markers in alcohol use disorder patients, as pioglitazone may offer benefit only to those with elevated inflammation.
- Reconsider the absolute avoidance of Z-drugs like zolpidem in critically ill delirious patients when severe insomnia is actively perpetuating cognitive decline.
- Proactively address medication adherence in bipolar disorder by targeting younger age, psychotic features, and comorbid substance use or anxiety as key risk factors for non-adherence.
- Monitor for potential clinical benefits of psilocybin in treatment-resistant depression cases where standard pharmacotherapies have failed.
- Leverage dopamine agonist augmentation strategies to address motivational symptoms in mood disorders that are refractory to conventional antidepressants.
- Incorporate sociodemographic and clinical correlates, such as lower education and personality disorders, into adherence counseling for patients with bipolar disorder.
Diagnosis & Treatment 1
This meta-analysis identifies clinical and sociodemographic correlates of poor medication adherence in bipolar disorder, highlighting that younger age, lower education, psychotic features, substance use disorders, and comorbid anxiety or personality disorders are associated with non-adherence.
Clinical Pearl 1
A randomized controlled trial found pioglitazone ineffective for reducing alcohol use or craving in adults with AUD overall, though a subgroup with elevated baseline inflammation showed benefit.